Presented interim data from the ongoing Phase 1 dose escalation study of PRT3789, its first-in-class IV SMARCA2 degrader, ...

In a report released today, Peter Lawson from Barclays maintained a Sell rating on Prelude Therapeutics (PRLD – Research Report), with a price target of $1.00. The company’s shares closed yesterday at ...

Analyst Reni Benjamin from JMP Securities reiterated a Buy rating on Prelude Therapeutics (PRLD – Research Report) and keeping the price ...

WILMINGTON, DE — Prelude Therapeutics Incorporated (Nasdaq: PRLD), a precision oncology company, has shared its third-quarter ...

PRLD stock touches 52-week low at $1.32 amid market challenges Prelude Therapeutics Inc (PRLD) stock has reached a 52-week low, trading at $1.32, as the biopharmaceutical company faces a ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Reveal insider sentiment with alternative data that tracks buy and sell trades made by top managers and company directors.

Dyne Therapeutics Inc.-2.70% $2.94B ...

Therapeutics are treatments used to alleviate or prevent a particular disease. Examples of therapeutics include drug therapy, medical devices, nutrition therapy and stem-cell therapies ...